MAR Stock Overview
A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.35 |
| 52 Week High | US$10.50 |
| 52 Week Low | US$4.20 |
| Beta | 0.0033 |
| 11 Month Change | 6.52% |
| 3 Month Change | -4.55% |
| 1 Year Change | 67.05% |
| 33 Year Change | -76.66% |
| 5 Year Change | n/a |
| Change since IPO | -75.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAR | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 9.7% | -0.8% | -1.4% |
| 1Y | 67.0% | 12.0% | 11.8% |
Return vs Industry: MAR exceeded the German Life Sciences industry which returned 12% over the past year.
Return vs Market: MAR exceeded the German Market which returned 11.8% over the past year.
Price Volatility
| MAR volatility | |
|---|---|
| MAR Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MAR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MAR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 580 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MAR fundamental statistics | |
|---|---|
| Market cap | €1.88b |
| Earnings (TTM) | -€122.90m |
| Revenue (TTM) | €259.22m |
4.1x
P/S Ratio-8.6x
P/E RatioIs MAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAR income statement (TTM) | |
|---|---|
| Revenue | US$278.59m |
| Cost of Revenue | US$148.40m |
| Gross Profit | US$130.19m |
| Other Expenses | US$262.27m |
| Earnings | -US$132.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 46.73% |
| Net Profit Margin | -47.41% |
| Debt/Equity Ratio | 67.3% |
How did MAR perform over the long term?
See historical performance and comparison